BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19247406)

  • 21. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
    Moul JW
    Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
    [No Abstract]   [Full Text] [Related]  

  • 22. Bicalutamide ('Casodex') development: from theory to therapy.
    Kolvenbag GJ; Furr BJ
    Cancer J Sci Am; 1997; 3(4):192-203. PubMed ID: 9263623
    [No Abstract]   [Full Text] [Related]  

  • 23. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hormone treatment of prostate cancer in Norway].
    Johansen TE; Berg C
    Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2558-62. PubMed ID: 19023350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
    Iversen P; Roder MA
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bicalutamide.
    Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17458049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
    J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
    [No Abstract]   [Full Text] [Related]  

  • 28. Combined androgen blockade: an update.
    Klotz L
    Urol Clin North Am; 2006 May; 33(2):161-6, v-vi. PubMed ID: 16631454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hormonal treatment of cancer of the prostate: review and present status].
    Ganzer R; Wieland WF; Bach T; Rössler W; Blana A
    Dtsch Med Wochenschr; 2007 Jan; 132(4):161-6. PubMed ID: 17230333
    [No Abstract]   [Full Text] [Related]  

  • 30. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.
    Petit JH; Gluck C; Kiger WS; Henry DL; Karasiewicz C; Talcott J; Berg S; Holupka E; Kaplan I
    Urol Oncol; 2008; 26(4):372-7. PubMed ID: 18367113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bicalutamide with radiotherapy for prostate cancer.
    Brower V
    Lancet Oncol; 2017 Mar; 18(3):e141. PubMed ID: 28190764
    [No Abstract]   [Full Text] [Related]  

  • 32. Re: Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
    Taneja SS
    J Urol; 2013 Sep; 190(3):880. PubMed ID: 23931194
    [No Abstract]   [Full Text] [Related]  

  • 33. Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate.
    Molenaar JP; Baten A; Blokx WA; Hoogendam A
    Eur Urol; 2009 Nov; 56(5):874-7; quiz 876. PubMed ID: 19171417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery).
    Parker C; Clarke N; Logue J; Payne H; Catton C; Kynaston H; Murphy C; Morgan R; Morash C; Parulekar W; Parmar M; Savage C; Stansfeld J; Sydes M;
    Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):167-71. PubMed ID: 17359901
    [No Abstract]   [Full Text] [Related]  

  • 35. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
    Curtis KK; Adam TJ; Chen SC; Pruthi RK; Gornet MK
    Aging Male; 2008 Dec; 11(4):157-61. PubMed ID: 18937151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bicalutamide-induced gynaecomastia: do we have the answer?
    Di Lorenzo G; Autorino R
    Eur Urol; 2007 Jul; 52(1):5-8. PubMed ID: 17258386
    [No Abstract]   [Full Text] [Related]  

  • 37. Photosensitive drug eruption induced by bicalutamide within the UVB action spectrum.
    Sasada K; Sakabe J; Tamura A; Kasuya A; Shimauchi T; Ito T; Hirakawa S; Tokura Y
    Eur J Dermatol; 2012; 22(3):402-3. PubMed ID: 22503957
    [No Abstract]   [Full Text] [Related]  

  • 38. Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge.
    Rapkiewicz A; Gorokhovsky R; Farcon E; Das K
    Diagn Cytopathol; 2008 Jul; 36(7):499-502. PubMed ID: 18528888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Digitate dermatosis responding to bicalutamide therapy.
    Malhomme de la Roche HJ; Bunker CB
    Clin Exp Dermatol; 2006 Jul; 31(4):590. PubMed ID: 16716171
    [No Abstract]   [Full Text] [Related]  

  • 40. Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature.
    Arce-Salinas C; Riesco-Martinez MC; Hanna W; Bedard P; Warner E
    J Clin Oncol; 2016 Feb; 34(4):e21-4. PubMed ID: 24888812
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.